ORLANDO, Fla. — Of the 12 biologics in four drug classes approved for treating psoriasis in the United States, interleukin 23 (IL-23) inhibitors might be exceptional, particularly if used early ...
Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials. The Protagonist Therapeutics-partnered IL-23 ...
Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing skin and easing symptom severity in patients with plaque psoriasis. Johnson ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback